CA2331036A1 - Spla2 inhibitor ester - Google Patents

Spla2 inhibitor ester Download PDF

Info

Publication number
CA2331036A1
CA2331036A1 CA002331036A CA2331036A CA2331036A1 CA 2331036 A1 CA2331036 A1 CA 2331036A1 CA 002331036 A CA002331036 A CA 002331036A CA 2331036 A CA2331036 A CA 2331036A CA 2331036 A1 CA2331036 A1 CA 2331036A1
Authority
CA
Canada
Prior art keywords
methyl
phenylmethyl
indol
oxy
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002331036A
Other languages
English (en)
French (fr)
Inventor
Daniel Jon Sall
Michael Lyle Denney
Jason Scott Sawyer
John Michael Morin Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2331036A1 publication Critical patent/CA2331036A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002331036A 1998-05-01 1999-04-20 Spla2 inhibitor ester Abandoned CA2331036A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8387398P 1998-05-01 1998-05-01
US60/083,873 1998-05-01
PCT/US1999/008538 WO1999056752A1 (en) 1998-05-01 1999-04-20 sPLA2 INHIBITOR ESTER

Publications (1)

Publication Number Publication Date
CA2331036A1 true CA2331036A1 (en) 1999-11-11

Family

ID=22181214

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002331036A Abandoned CA2331036A1 (en) 1998-05-01 1999-04-20 Spla2 inhibitor ester

Country Status (22)

Country Link
EP (1) EP1073440B1 (cg-RX-API-DMAC10.html)
JP (1) JP4459441B2 (cg-RX-API-DMAC10.html)
KR (1) KR20010071197A (cg-RX-API-DMAC10.html)
CN (1) CN1303290A (cg-RX-API-DMAC10.html)
AT (1) ATE280155T1 (cg-RX-API-DMAC10.html)
AU (1) AU755901B2 (cg-RX-API-DMAC10.html)
BR (1) BR9910149A (cg-RX-API-DMAC10.html)
CA (1) CA2331036A1 (cg-RX-API-DMAC10.html)
DE (1) DE69921314T2 (cg-RX-API-DMAC10.html)
EA (1) EA003277B1 (cg-RX-API-DMAC10.html)
ES (1) ES2230847T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20000738A2 (cg-RX-API-DMAC10.html)
HU (1) HUP0201636A1 (cg-RX-API-DMAC10.html)
ID (1) ID27812A (cg-RX-API-DMAC10.html)
IL (1) IL139203A0 (cg-RX-API-DMAC10.html)
NO (1) NO315940B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ507391A (cg-RX-API-DMAC10.html)
PL (1) PL344571A1 (cg-RX-API-DMAC10.html)
SK (1) SK16332000A3 (cg-RX-API-DMAC10.html)
TR (1) TR200003198T2 (cg-RX-API-DMAC10.html)
WO (1) WO1999056752A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200005561B (cg-RX-API-DMAC10.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456824A (zh) * 2014-05-22 2017-02-22 宝洁公司 包含泡沫的异质块体
US11173078B2 (en) 2015-11-04 2021-11-16 The Procter & Gamble Company Absorbent structure
US11376168B2 (en) 2015-11-04 2022-07-05 The Procter & Gamble Company Absorbent article with absorbent structure having anisotropic rigidity
US11957556B2 (en) 2015-06-30 2024-04-16 The Procter & Gamble Company Absorbent structure
US12491123B2 (en) 2015-11-04 2025-12-09 The Procter & Gamble Company Absorbent structure

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
WO2001044185A1 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Carbon monoxide-based synthesis of spla2 inhibitors
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
EP2154958A4 (en) * 2007-05-03 2011-05-04 Anthera Pharmaceuticals Inc TREATMENT OF HEART CIRCULATION DISEASES AND DYSLIPIDEMIA WITH INHIBITORS OF SECRETARY PHOSPHOLIPASE A2 (SPLA2) AND SPLA2 HEMMER COMBINATION THERAPIES
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
EP1950200B1 (en) * 1994-04-01 2012-01-11 Eli Lilly And Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
CA2358492A1 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456824A (zh) * 2014-05-22 2017-02-22 宝洁公司 包含泡沫的异质块体
US11957556B2 (en) 2015-06-30 2024-04-16 The Procter & Gamble Company Absorbent structure
US11173078B2 (en) 2015-11-04 2021-11-16 The Procter & Gamble Company Absorbent structure
US11376168B2 (en) 2015-11-04 2022-07-05 The Procter & Gamble Company Absorbent article with absorbent structure having anisotropic rigidity
US12491123B2 (en) 2015-11-04 2025-12-09 The Procter & Gamble Company Absorbent structure

Also Published As

Publication number Publication date
NO20005477D0 (no) 2000-10-31
NO20005477L (no) 2000-10-31
WO1999056752A1 (en) 1999-11-11
JP4459441B2 (ja) 2010-04-28
ES2230847T3 (es) 2005-05-01
EP1073440A4 (en) 2002-07-17
AU755901B2 (en) 2003-01-02
DE69921314D1 (de) 2004-11-25
HUP0201636A1 (en) 2002-09-28
DE69921314T2 (de) 2006-02-09
IL139203A0 (en) 2001-11-25
PL344571A1 (en) 2001-11-05
JP2002513761A (ja) 2002-05-14
EP1073440A1 (en) 2001-02-07
BR9910149A (pt) 2001-10-02
AU3652599A (en) 1999-11-23
EA200001141A1 (ru) 2001-04-23
KR20010071197A (ko) 2001-07-28
NO315940B1 (no) 2003-11-17
SK16332000A3 (sk) 2001-06-11
ZA200005561B (en) 2002-01-10
ATE280155T1 (de) 2004-11-15
TR200003198T2 (tr) 2001-03-21
EA003277B1 (ru) 2003-04-24
ID27812A (id) 2001-04-26
NZ507391A (en) 2003-12-19
HRP20000738A2 (en) 2001-10-31
EP1073440B1 (en) 2004-10-20
CN1303290A (zh) 2001-07-11

Similar Documents

Publication Publication Date Title
CA2146097C (en) 1h-indole-3-glyoxylamide spla2 inhibitors
EP0772592B1 (en) 1H-INDOLE-1-FUNCTIONAL sPLA 2 INHIBITORS
US5684034A (en) 1H-indole-3-acetamide sPLA2 inhibitors
US5578634A (en) 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors
EP1073440B1 (en) sPLA 2 INHIBITOR ESTERS
US6353128B1 (en) Phenyl acetamides as sPLA2 inhibitors
EP1202963B1 (en) Spla2 inhibitors
US6274578B1 (en) sPLA2 inhibitor ester
US6274616B1 (en) N,N-diethylglycolamido ester prodrugs of indole sPLA2 inhibitors
US6140327A (en) Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
CN101827814A (zh) 新颖的氨基甲酰甘氨酸衍生物
MXPA00010465A (en) sPLA2
WO1999021545A1 (en) ISOPROPYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
CZ20004051A3 (cs) Ester jako inhibitor sPLA2

Legal Events

Date Code Title Description
FZDE Discontinued